Meet the Inventor

Giuseppe Marineo

Professor Giuseppe Marineo, at the Medical Bioengineering Research Center in Rome, is the inventor of Calmare Pain Relief Therapy, which is a medical device for electronic nerve stimulation that “scrambles” pain sensations sent to the central nervous system. This device, known as the Calmare MC-5A, is 100% safe and non-invasive and is used to treat high intensity oncologic and neuropathic pain, including pain resistant to morphine, without the adverse and harmful side effects linked to narcotic painkillers. Professor Marineo, a researcher and bioengineer, theorized that the concept of disease (and its corresponding treatment) should be looked at from a biophysical point of view rather than a chemical (medical) or mechanical (surgical) viewpoint.

Calmare scrambler therapy is performed using external electric stimulation to manipulate the signals flowing to the central nervous system. The process is transmitted through electrodes, similar to those used for an EKG (electrocardiogram). This low dose electricity “scrambles” pain messages sent to the brain replacing “pain” with a “no-pain” message. Therapy is performed for a minimum of 10 daily sessions, lasting 30 – 45 minutes in duration, on average.

The FDA has cleared the use of Marineo’s Calmare Pain Relief Therapy in the United States. It is appropriate for patients suffering from cancer and chemotherapy pain, pain as a result of chronic diseases such as diabetes, multiple sclerosis and arthritis, back and neck pain, failed back surgery syndrome, phantom limb pain and more.

Calmare therapy, performed on more than 3,000 patients worldwide, received FDA 510(k) clearance and medical device CE certification from the European Union. The Journal of Clinical Oncology recently reported Calmare therapy to be effective in helping cancer patients overcome chronic pain. Select U.S. hospitals, cancer treatment centers and pain management facilities now offer Calmare therapy, including Walter Reed Army Medical Center and the Mayo Clinic.

  • dfsghdsfgh